Loading
A phase 3 trial testing YL201 in small-cell lung cancer and non-small-cell lung cancer, now recruiting.
A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer is a phase 3 interventional study registered as NCT07739758, led by MediLink Therapeutics (Suzhou) with Shanghai Henlius Biotech, and recruiting on the registry. Official title: A Phase III, Multicenter, Randomised, Controlled, Open-label Clinical Study to Evaluate the Efficacy and Safety of YL201 in Combination With Serplulimab Versus Carboplatin and Etoposide in Combination With Serplulimab as First-line Treatment in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer. Planned enrolment is 442 participants (estimated). The study started in 2026-08-18 and primary completion is expected in 2029-06. No results have been posted on ClinicalTrials.gov.
Shares YL201, MediLink Therapeutics, Small-cell lung cancer, Non-small-cell lung cancer.
Shares YL201, MediLink Therapeutics.
Shares YL201, MediLink Therapeutics.
Shares YL201, MediLink Therapeutics.
Shares YL201, MediLink Therapeutics, Non-small-cell lung cancer.
Shares YL201, MediLink Therapeutics.
Shares MediLink Therapeutics, Small-cell lung cancer, Non-small-cell lung cancer.
Shares MediLink Therapeutics, Small-cell lung cancer, Non-small-cell lung cancer.